NAD Tablet Receives MFDS Approval as Korea’s First Niacin-Based Complex
Date : 26/02/13
NAD Tablet, Korea's first niacin-based combination product,
received product approval from the Ministry of Food and Drug Safety on January 19, 2026.
NAD Tablet is a combination product designed to efficiently promote the biosynthesis of
NAD⁺(nicotinamide adenine dinucleotide), a substance known to regulate aging.
NAD Tablet contains both niacin (nicotinic acid) and niacinamide (nicotinamide),
each of which increases NAD⁺ levels through their own biochemical mechanisms.
NAD⁺ is a key regulator of various biological metabolic processes,
including cellular energy metabolism (ATP production), DNA damage repair, antioxidant activity, and immune regulation.
It is gaining significant attention as the "Molecule of Life and Youth."
As we age, NAD⁺ levels naturally decline, which can lead to cellular aging, metabolic decline, and the development of age-related diseases.
Developed against this backdrop, NAD Tablet is Korea's first niacin-based complex supplement
that optimizes the body's NAD⁺ levels, helping to support cellular energy metabolism and delay aging.
NAD Tablet is scheduled for launch and sales in 2026 and is expected to offer a new alternative
to the trend of extending healthy lifespans beyond 100 and toward an era of 120 years of life.
NAD⁺: Nicotinamide Adenine Dinucleotide